IRMD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

21.60M

+11.39%

0.435

+8.75%

20.79M

+6.56%

0.415

+12.16%

21.83M

+6.96%

0.440

-2.22%

Estimates Revision

The market is revising Upward the revenue expectations for IRADIMED CORPORATION (IRMD) for FY2025, with the revenue forecasts being adjusted by 2.36% over the past three months. During the same period, the stock price has changed by 31.20%.

Revenue Estimates for FY2025

Revise Upward

+2.36%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.74%

In Past 3 Month

Stock Price

Go Up

+31.20%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast IRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRMD is 99.00 USD with a low forecast of 98.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

98.00

Averages

99.00

High

100.00

Current: 0.000

Low

98.00

Averages

99.00

High

100.00

Roth Capital

Buy

maintain

$90 -> $98

2025-11-04

Reason

Roth Capital

Price Target

$90 -> $98

2025-11-04

maintain

Buy

Reason

Roth Capital raised the firm's price target on iRadimed to $98 from $90 and keeps a Buy rating on the shares after its Q3 earnings beat. Legacy pump sales remain strong despite the planned full launch of the next generation version in Q1, monitor sales accelerated in the quarter, and there could be nice uplift from the cross-selling the next gen pump into non-user hospitals, the analyst tells investors in a research note.

Lake Street

Buy

maintain

$75 -> $100

2025-11-03

Reason

Lake Street

Price Target

$75 -> $100

2025-11-03

maintain

Buy

Reason

Lake Street raised the firm's price target on iRadimed to $100 from $75 and keeps a Buy rating on the shares after a top and bottom line beat with revenue and EPS guidance increased in Q3. While acknowledging that shares trade at a premium valuation, the firm sees a record backlog providing near-term visibility and the new 3870 IV Pump launch driving growth acceleration in 2026, the analyst tells investors.

Roth Capital

Kyle Bauser

Buy

maintain

$90 -> $98

2025-11-03

Reason

Roth Capital

Kyle Bauser

Price Target

$90 -> $98

2025-11-03

maintain

Buy

Reason

Roth Capital analyst Kyle Bauser raised the firm's price target on iRadimed to $98 from $90 and keeps a Buy rating on the shares, citing higher forward estimates and confidence in the business after the company reported Q3 sales and EPS above the firm's and consensus estimates and raised full-year guidance.

Roth Capital

Kyle Bauser

initiated

$90

2025-10-31

Reason

Roth Capital

Kyle Bauser

Price Target

$90

2025-10-31

initiated

Reason

Roth Capital analyst Kyle Bauser resumed coverage of iRadimed with a Buy rating and $90 price target. The firm expects the company to benefit from the launch of its next-gen non-magnetic IV infusion pump. The pump has "significant enhancements" and a premium selling price versus the older version, the analyst tells investors in a research note.

Roth MKM

Jason Wittes

Strong Buy

Reiterates

$60 → $72

2025-02-14

Reason

Roth MKM

Jason Wittes

Price Target

$60 → $72

2025-02-14

Reiterates

Strong Buy

Reason

Roth MKM raised the firm's price target on iRadimed to $72 from $60 and keeps a Buy rating on the shares. The company reported solid Q4 revenue of $19.4M, representing an 11% y/y increase while beating the firm's estimate and consensus of $19.1M as well as previously issued guidance of $19.2M-$19.4M for FY24, the analyst tells investors in a research note. Monitoring system bookings also improved in Q4, signaling early traction from iRadimed's renewed salesforce focus on this product category, the firm adds.

Valuation Metrics

The current forward P/E ratio for IRadimed Corp (IRMD.O) is 53.06, compared to its 5-year average forward P/E of 37.63. For a more detailed relative valuation and DCF analysis to assess IRadimed Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

37.63

Current PE

53.06

Overvalued PE

47.01

Undervalued PE

28.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

8.61

Current PS

13.81

Overvalued PS

10.34

Undervalued PS

6.88

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

IRMD News & Events

Events Timeline

No data

News

9.5

2025-11-28NASDAQ.COM

Transcript of IRadimed (IRMD) Earnings Call for Q3 2025

8.0

2025-11-12NASDAQ.COM

Upcoming Ex-Dividend Dates for Duke Energy, American States Water, and iRadimed

4.5

2025-11-10Newsfilter

IRADIMED CORPORATION Recognized in TIME's 2026 List of America's Growth Leaders

People Also Watch

Frequently Asked Questions

What is IRadimed Corp (IRMD) stock price today?

The current price of IRMD is 98.95 USD — it has decreased -1.05 % in the last trading day.

What is IRadimed Corp (IRMD)'s business?

IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories and services. Its MRidium 3860+ MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss.

What is the price predicton of IRMD Stock?

What is IRadimed Corp (IRMD)'s revenue for the last quarter?

IRadimed Corp revenue for the last quarter amounts to 21.20M USD, increased 15.69 % YoY.

What is IRadimed Corp (IRMD)'s earnings per share (EPS) for the last quarter?

IRadimed Corp. EPS for the last quarter amounts to 0.43 USD, increased 7.50 % YoY.

What changes have occurred in the market's expectations for IRadimed Corp (IRMD)'s fundamentals?

How many employees does IRadimed Corp (IRMD). have?

IRadimed Corp (IRMD) has 160 emplpoyees as of January 10 2026.

What is IRadimed Corp (IRMD) market cap?

Today IRMD has the market capitalization of 1.26B USD.